2. Academic Validation
  3. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor

In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor

  • Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. doi: 10.1016/j.prostaglandins.2013.02.001.
Patricia L Podolin 1,  Brian J Bolognese,  Joseph F Foley,  Edward Long 3rd,  Brian Peck,  Sandra Umbrecht,  Xiaojun Zhang,  Penny Zhu,  Benjamin Schwartz,  Wensheng Xie,  Chad Quinn,  Hongwei Qi,  Sharon Sweitzer,  Stephanie Chen,  Marc Galop,  Yun Ding,  Svetlana L Belyanskaya,  David I Israel,  Barry A Morgan,  David J Behm,  Joseph P Marino Jr,  Edit Kurali,  Mary S Barnette,  Ruth J Mayer,  Catherine L Booth-Genthe,  James F Callahan
Affiliations

Affiliation

  • 1 Stress & Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, PA 19406, USA. patty.podolin@gsk.com
PMID: 23434473 DOI: 10.1016/j.prostaglandins.2013.02.001
Abstract

Soluble Epoxide Hydrolase (sEH, EPHX2) metabolizes eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs), and leukotoxin (LTX) to leukotoxin diol (LTX diol). EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects and vasodilation. A novel, potent, selective inhibitor of recombinant human, rat and mouse sEH, GSK2256294A, exhibited potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET in human, rat and mouse whole blood in vitro, and a dose-dependent increase in the LTX/LTX diol ratio in rat plasma following oral administration. Mice receiving 10 days of cigarette smoke exposure concomitant with oral administration of GSK2256294A exhibited significant, dose-dependent reductions in pulmonary leukocytes and keratinocyte chemoattractant (KC, CXCL1) levels. Mice receiving oral administration of GSK2256294A following 10 days of cigarette smoke exposure exhibited significant reductions in pulmonary leukocytes compared to vehicle-treated mice. These data indicate that GSK2256294A attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resolution. Collectively, these data indicate that GSK2256294A would be an appropriate agent to evaluate the role of sEH in clinical studies, for example in diseases where cigarette smoke is a risk factor, such as chronic obstructive pulmonary disease (COPD) and Cardiovascular Disease.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z